Anemia and anemia correction: Surrogate markers or causes of morbidity in chronic kidney disease?

Nature Clinical Practice Nephrology

Volumn 4, Issue 8, 2008, Pages 436-445

  Vaziri, Nosratola D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Drug overdose; Erythropoietin; Intravenous iron; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN; ENDOTHELIN; ENDOTHELIN 1; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN; PROTEIN C; RECOMBINANT ERYTHROPOIETIN; RENIN; THROMBOXANE; TRANSFERRIN;

ANEMIA; ANGIOGENESIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE MARKER; DRUG MEGADOSE; DRUG OVERDOSE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INFLAMMATION; MORBIDITY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANEMIA; ANIMALS; BLOOD PLATELETS; BLOOD PRESSURE; CAUSALITY; CHRONIC DISEASE; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; HYPERTENSION; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MORBIDITY; NITRIC OXIDE; OVERDOSE; OXIDATIVE STRESS;

EID: 47949102655     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0847     Document Type: Review

References (116)

1. Besarab A (2001) Anemia of renal disease. In Diseases of the Kidney and Urinary Tract, edn 7, 2719-2734 (Ed. Schrier RW) Philadelphia: Lippincott, Williams & Wilkins
2. Stenvinkel P (2001) The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 16: 36-40
3. Locatelli F et al. (2006) Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 21: 991-998
4. Attallah N et al. (2006) Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis 47: 644-654
5. Lin CL et al. (2003) Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ren Fail 25: 445-453
6. Himmelfarb J et al. (2002) The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538
7. Himmelfarb J and Hakim RM (2003) Oxidative stress in uremia. Curr Opin Nephrol Hypertens 12: 593-598
8. Stenvinkel P (2006) Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 11: 36-41
9. Lim PS et al. (2002) Mitochondrial DNA mutations and oxidative damage in skeletal muscle of patients with chronic uremia. J Biomed Sci 9: 549-560
10. Vaziri ND (2004) Oxidative stress in uremia: nature, mechanisms and potential consequences. Semin Nephrol 24: 469-473
11. Vaziri ND (2004) Roles of oxidative stress and antioxidant therapy in chronic renal disease and hypertension. Curr Opin Nephrol Hypertens 13: 93-99
12. 1 receptor, oxidative stress, inflammation and progressive injury in renal mass reduction. J Pharmacol Exp Ther 323: 85-93
13. Yoon JW et al. (2007) Spontaneous leukocyte activation and oxygen-free radical generation in end stage renal disease. Kidney Int 71: 167-172
14. Vaziri ND et al. (2003) Oxidative stress and dysregulation of superoxide dismutase and NAD(P)H oxidase in renal insufficiency. Kidney Int 63: 179-185
15. Vaziri ND et al. (2002) Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 39: 135-141
16. Quiroz Y et al. (2008) Melatonin ameliorates oxidative stress, inflammation, proteinuria and progression of renal damage in rats with renal mass reduction. Am J Physiol Renal Physiol 294: F336-F344
17. Herrera J et al. (2001) Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 37: 750-757
18. Chen HC et al. (1997) Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients. Kidney Int 52: 1390-1394
19. Scalera F et al. (2005) Erythropoietin increases asymmetric dimethylarginine in endothelial cells: role of dimethylarginine dimethylaminohydrolase. J Am Soc Nephrol 16: 892-898
20. Lim CS and Vaziri ND (2004) Iron and oxidative stress in renal insufficiency. Am J Nephrol 24: 569-575
21. Lim CS and Vaziri ND (2004) The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 65: 1802-1809
22. Lim PS et al. (1999) Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 14: 2680-2687
23. Galleano M and Puntarulo S (1995) Role of antioxidants on the erythrocytes resistance to lipid peroxidation after acute iron overload in rats. Biochim Biophys Acta 1271: 321-326
24. Bishu K and Agarwal R (2006) Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 1 (Suppl 1): S19-S23
25. Ma JZ et al. (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619
26. Xia H et al. (1999) Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10: 1309-1316
27. Collins AJ et al. (2001) Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12: 2465-2473
28. Li S and Collins AJ (2004) Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. Kidney Int 65: 626-633
29. Ofsthun N et al. (2003) The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 63: 1908-1914
30. Li S et al. (2004) Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int 65: 1864-1869
31. Robinson BM et al. (2005) Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 68: 2323-2330
32. Locatelli F et al. (2004) Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19: 121-132
33. Wolfe RA et al. (2005) Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis 45: 127-135
34. [No authors listed] (2001) IV. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 (Suppl 1): S182-S238
35. KDOQI (2006) KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 (Suppl 3): S11-S145
36. Besarab A et al. (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590
37. Drueke TB et al. (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084
38. Singh AK et al. (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098
39. Phrommintikul A et al. (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369: 381-388
40. Strippoli GF et al. (2004) Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15: 3154-3165
41. Volkova N and Arab L (2006) Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 47: 24-36
42. Parfrey PS (2006) Target hemoglobin level for EPO therapy in CKD. Am J Kidney Dis 47: 171-173
43. Pisoni RL et al. (2004) Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 94-111
44. KDOQI (2007) KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50: 471-530
45. Deng G et al. (2001) Increased tyrosine nitration of the brain in chronic renal insufficiency: reversal by antioxidant therapy and angiotensin-converting enzyme inhibition. J Am Soc Nephrol 12: 1892-1899
46. Vaziri ND et al. (1998) Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 53: 1748-1754
47. Sindhu RK et al. (2004) Effect of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochim Biophys Acta 1690: 231-237
48. Sindhu RK and Vaziri ND (2003) Upregulation of cytochrome P450 1A2 in chronic renal failure: does oxidized tryptophan play a role? Adv Exp Med Biol 527: 401-407
49. Rodriguez-Iturbe B et al. (2005) Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int 68: 2131-2142
50. Vaziri ND and Khan M (2007) Interplay of reactive oxygen species and nitric oxide in the pathogenesis of experimental lead-induced hypertension. Clin Exp Pharmacol Physiol 34: 920-925
51. Schiffrin EL et al. (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116: 85-97
52. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352: 1685-1695
53. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874
54. Shah PK (2003) Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41 (Suppl): S15-S22
55. Aikawa M and Libby P (2004) The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 13: 125-138
56. Vaziri ND and Rodríguez-Iturbe B (2006) Mechanisms of Disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat Clin Pract Nephrol 2: 582-593
57. Yoon JW et al. (2006) Naïve and central memory T cell lymphopenia in end-stage renal disease. Kidney Int 70: 371-376
58. Ansell BJ et al. (2007) The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18: 427-434
59. Navab M et al. (2006) Mechanisms of Disease: proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab 2: 504-511
60. Kalantar-Zadeh K et al. (2007) HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 72: 1149-1156
61. Ganz T (2007) Molecular control of iron transport. J Am Soc Nephrol 18: 394-400
62. Hardee ME et al. (2006) Erythropoietin biology in cancer. Clin Cancer Res 12: 332-339
63. Vaziri ND (1999) Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 33: 821-828
64. Vaziri ND (2001) Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens 10: 633-637
65. Lebel M et al. (1998) Hemodynamic and hormonal changes during erythropoietin therapy in hemodialysis patients. J Am Soc Nephrol 9: 97-104
66. Vaziri ND et al. (1996) Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol Endocrinol Metab 271: E113-E122
67. Vaziri ND et al. (1995) In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol 269: F838-F845
68. Neusser M et al. (1993) Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res 27: 1233-1236
69. Kaupke CJ et al. (1994) Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4: 1874-1878
70. Takahashi K et al. (1993) Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin. Clin Sci 84: 47-50
71. Bode-Böger SM et al. (1996) Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50: 1255-1261
72. Carlini RG et al. (1993) Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43: 1010-1014
73. Carlini RG et al. (1995) Endothelin-1 release by erythropoietin involves calcium signaling in endothelial cells. J Cardiovasc Pharmacol 26: 889-892
74. Lebel M et al. (1998) Plasma and blood vessel endothelin-1 concentrations in hypertensive uremic rats treated with erythropoietin. Clin Exp Hypertens 20: 939-951
75. Katoh K et al. (1994) Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 54: 253-259
76. Brochu E et al. (1999) Differential effects of endothelin-1 antagonists on erythropoietin-induced hypertension in renal failure. J Am Soc Nephrol 10: 1440-1446
77. Eggena P et al. (1991) Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 261: E642-E646
78. Barrett JD et al. (1998) Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells. J Hypertens 16: 1749-1757
79. Kuriyama S et al. (2001) Association of angiotensinogen gene polymorphism with erythropoietin-induced hypertension: a preliminary report. Hypertens Res 24: 501-505
80. Lebel M et al. (2006) Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens 19: 1286-1292
81. Rodrigue ME et al. (2003) Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol 41: 388-395
82. Rodrigue ME et al. (2005) Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. Can J Physiol Pharmacol 83: 467-475
83. Anagnostou A et al. (1990) Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A 87: 5978-5982
84. Nagai T et al. (1995) Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 10: 1814-1819
85. Carlini RG et al. (1999) Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55: 546-553
86. Wang XQ and Vaziri ND (1999) Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33: 894-899
87. Gogusev J et al. (1994) Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 199: 977-983
88. Ammarguellat F et al. (1996) Direct effect of erythropoietin on rat vascular smooth-muscle cell via a putative erythropoietin receptor. Nephrol Dial Transplant 11: 687-692
89. Akimoto T et al. (2001) Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells. J Hypertens 19: 193-202
90. Carlini RG et al. (1995) Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int 47: 740-745
91. Satoh K et al. (2006) Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 113: 1442-1450
92. Yatsiv I et al. (2005) Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 19: 1701-1703
93. van der Meer P et al. (2004) Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur J Heart Fail 6: 853-859
94. Vaziri ND et al. (1994) Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 266: F360-F366
95. Zhu X and Perazella MA (2006) Nonhematologic complications of erythropoietin therapy. Semin Dial 19: 279-284
96. Kase S et al. (2007) Expression of erythropoietin receptor in human epiretinal membrane of proliferative diabetic retinopathy. Br J Ophthalmol 91: 1376-1378
97. Nagarajan S et al. (2007) Transplant reno-vascular stenoses associated with early erythropoietin use. Clin Transplant 21: 597-608
98. Bittorf T et al. (2001) Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance. Cell Signal 13: 673-681
99. Chen HC et al. (1997) Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients. Kidney Int 52: 1390-1394
100. Kaupke CJ et al. (1996) Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 3: 1672-1679
101. Stohlawetz PJ et al. (2000) Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 95: 2983-2989
102. Zhou XJ and Vaziri ND (2002) Defective calcium signalling in uraemic platelets and its amelioration with long-term erythropoietin therapy. Nephrol Dial Transplant 17: 992-997
103. Kahraman S et al. (2005) Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients. Nephrology (Carlton) 10: 264-269
104. Nagai T et al. (1996) rHuEPO enhances the production of plasminogen activator inhibitor-1 in cultured endothelial cells. Kidney Int 50: 102-107
105. Borawski J et al. (2002) Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy. Clin Appl Thromb Hemost 8: 359-367
106. Fusté B et al. (2002) Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 88: 678-685
107. Wang XQ and Vaziri ND (1999) Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension 33: 894-899
108. Ni Z et al. (1998) Nitric oxide metabolism in erythropoietin- induced hypertension: effect of calcium channel blockade. Hypertension 32: 724-729
109. Zager RA et al. (2002) Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 40: 90-103
110. Tovbin D et al. (2002) Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 40: 1005-1012
111. Carlini RG et al. (2006) Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. Nephrol Dial Transplant 21: 3055-3061
112. Rooyakkers TM et al. (2002) Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 32 (Suppl 1): 9-16
113. Drueke T et al. (2002) Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217
114. Zhou XJ et al. (2000) Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 80: 1905-1914
115. Agarwal R et al. (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65: 2279-2289
116. Patruta SI and Hörl WH (1999) Iron and infection. Kidney Int Suppl 69: S125-S130